Metastatic Renal Cell Carcinoma Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Metastatic Renal cell carcinoma

IndicationStatusPhase
DBCOND0030098 (Metastatic Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03595124A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Treatment
NCT04090710SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerTreatment
NCT03126331Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabTreatment
NCT03075423Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCTreatment
NCT03013335Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenTreatment